% 0 Richard Lipton期刊文章% %约书亚·科恩%一个Ronghua杨保罗·P·杨% % Verena Ramirez Campos迈克尔Seminerio % % Rashmi Halker辛格%杰西卡Ailani % T Fremanezumab的长期疗效的患者恢复从慢性偏头痛的情景分类(S17.006) % D J神经病学2019% % P S17.006 % V 92% N 15补充% X目的:评价的长期疗效Fremanezumab成人慢性偏头痛(CM)恢复情景偏头痛(EM)。首页背景:CM经验更频繁头痛患者和残疾大于EM患者。Fremanezumab,全人源化单克隆抗体(IgG2Δa)选择性目标降钙素相关基因肽(CGRP怎样),在美国被批准用于偏头痛的预防治疗。设计/方法:52周,多中心,随机,双盲,与这些相应平行的组织研究,CM患者接受皮下fremanezumab月(每月225毫克;的起始剂量675毫克)或季度(675毫克每3个月)。这事后分析评价fremanezumab功效的子群病人恢复从CM EM,定义为≥15月头痛天基线和< 15头痛的日子在12月。结果:813 CM患者基线,548年恢复从CM。在这个群,平均每月的头痛天数的变化至少中等严重程度从基线到6月是季度和7.7−−7.6月度计量,从基线到12月是季度和8.5−−8.8月剂量。平均每月的偏头痛天数变化从基线到6月是季度和−−8.9 9.2每月计量;从基线为季度和月12是−10.3−10.4月剂量。任何急性头痛药物使用均值变化从基线到6月是季度和−−7.0 7.2每月计量;从基线为季度和月12是−8.2−8.1月剂量。结论:在患者恢复从CM EM,每月头痛,偏头痛的天,天的急性头痛药物的使用逐渐减少从基线到6月和12月通过剂量组。披露:立顿博士已经收到个人赔偿咨询、担任科学顾问委员会说,与美国神经病学学会或其他活动,桤木生物制药,爱力根,美国头痛学会安进,自主技术,Avanir制药、Biohaven, Biovision,波士顿科学,Reddy博士的,Electrocore,礼来,eNeura疗法,默克,Pernix,辉瑞、葛兰素史克Supernus, Teva首页, Trigemina,向量,韦丹塔。 Dr. Lipton holds stock and/or stock options in Biohaven. Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Teva Pharmaceuticals. Dr. Yeung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Yang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Seminerio has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities as an employee of Teva Pharmaceuticals. Dr. Ramirez Campos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Halker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with WebMD/Medlink, Amgen, and Allergan. Dr. Halker has received personal compensation in an editorial capacity for Current Neurology & Neuroscience Reports. Dr. Ailani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder, Allergan, Amgen, Avanir, Biohavin, Eli Lilly and Company, Electrocore, Promius, Teva, Impel, Satsuma, Aptus, Alpha Sites and Miller Medical Communications. Dr. Ailani has received personal compensation in an editorial capacity for Current Pain and Headache Reports (section editor). Dr. Ailani has received research support from ARMR/American Migraine Foundation and Biohaven. %U